Please login to the form below

Not currently logged in
Email:
Password:

Jonathan Fox leaves AstraZeneca for MyoKardia

Will lead programme to target genetic heart disease

Jonathan Fox, MyoKardiaMyoKardia has appointed former VP, clinical development at AstraZeneca Jonathan Fox to chief medical officer.

In his new role, Dr Fox will lead the development of the US biopharma's pipeline of small molecule therapeutics that focus on the treatment of genetic cardiovascular disease.

It's an area that Dr Fox has great experience, having served as senior director, clinical cardiovascular research at Merck & Co and director of clinical pharmacology at SmithKline Beecham, in addition to his time at AstraZeneca.

On top of this industry experience, Dr Fox has been a clinical professor of medicine at the University of Pennsylvania's School of Medicine for the past two decade.

He also served for four years as the industry representative to the FDA's Cardiovascular and renal Drug Products Advisory Committee.

Commenting on his appointment, he highlighted MyoKardia's potential in treating genetic heart disease.

“MyoKardia's genetically targeted approach and cutting-edge platform has the potential to fundamentally change the lives of patients with hypertrophic cardiomyopathy and dilated cardiomyopathy,” he said.

“By translating the groundbreaking science of the founding investigators into effective, disease modifying treatments, we may ultimately transform the future of treating cardiovascular disease.”

1st February 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics